A team of pediatric researchers in Wuhan, China, has identified a set of blood-borne proteins that could help doctors detect fatty liver disease in children with obesity without resorting to invasive procedures. The study, published in BMC Pediatrics, examined five circulating cardiometabolic biomarkers and found that three of them—cathepsin D, leptin, and growth differentiation factor 15—were independently associated with metabolic dysfunction-associated steatotic liver disease, or MASLD, in a cohort of children aged six to fourteen. The findings point toward a future in which a simple blood draw, combined with routine clinical measurements, might flag which young patients need closer monitoring of their liver health.
MASLD has become one of the most common chronic liver conditions in the pediatric population, tracking closely with the global rise in childhood obesity. The disease involves the abnormal accumulation of fat within liver cells and, in a subset of patients, can progress to inflammation, fibrosis, and eventually cirrhosis. The challenge for clinicians is that the liver is remarkably silent in its early stages: children with accumulating hepatic fat typically feel well, and standard liver enzymes such as alanine aminotransferase can remain within normal limits even when fat infiltration is well established. The current diagnostic gold standard, liver biopsy, is rarely justified in children because of its invasiveness, cost, and sampling variability. Abdominal ultrasound is the usual screening tool, but it is operator-dependent and loses sensitivity when hepatic fat content is modest. This diagnostic gap is precisely what the Chinese team set out to address.
The researchers, led by Huanyu Wang and Zongming Yang of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, with corresponding authors Shimin Wu and Xiaoping Luo, conducted a cross-sectional study of children with obesity who presented to the hospital’s Department of Pediatrics between January 2023 and September 2024. The final analysis included 84 children, 53 boys and 31 girls, of whom 43—just over half—were diagnosed with MASLD based on abdominal ultrasound findings. Each child underwent anthropometric assessment, including body mass index z-score and waist-to-height ratio, alongside fasting metabolic panels. The team then quantified serum concentrations of five candidate biomarkers using enzyme-linked immunosorbent assays: cathepsin D, leptin, adiponectin, insulin-like growth factor 1, and growth differentiation factor 15.
These five molecules were not chosen at random. Each represents a distinct biological axis implicated in obesity-related liver disease. Cathepsin D is a lysosomal protease involved in intracellular protein degradation, and emerging evidence links it to lipid metabolism, insulin signaling, and hepatic inflammation. Leptin, the prototypical adipocyte-derived hormone, signals energy stores to the brain and participates in immune and fibrotic pathways in the liver. Adiponectin, another adipokine, is generally insulin-sensitizing and anti-inflammatory, and its levels tend to fall as metabolic health deteriorates. Insulin-like growth factor 1 mediates growth hormone action and is often altered in states of insulin resistance. Growth differentiation factor 15 is a stress-responsive cytokine of the transforming growth factor beta superfamily that rises in mitochondrial stress and systemic inflammation, and it has attracted attention as a broad marker of cardiometabolic risk.
The statistical approach was deliberately conservative. Rather than simply asking whether biomarker levels differed between children with and without MASLD, the investigators calculated odds ratios across tertiles of each biomarker after adjusting for established risk factors: age, sex, body mass index z-score, and waist-to-height ratio. This adjustment matters because any marker that merely reflects the degree of obesity adds little clinical value; the question was whether these proteins carry independent information about liver fat beyond what a clinician already knows from measuring a child’s size. The team also tested the shape of each association, allowing for nonlinear relationships rather than assuming a straight line.
The results were striking for cathepsin D. Children in the highest tertile of logarithmically transformed serum CTSD had roughly twelve-fold higher odds of MASLD compared with those in the lowest tertile, with an odds ratio of 12.63 and a 95 percent confidence interval spanning 2.57 to 84.62, and the association was linear across the distribution. Growth differentiation factor 15 also showed a robust positive association: children in the top tertile had nearly five times the odds of MASLD relative to the bottom tertile, with an odds ratio of 4.86 and a confidence interval of 1.14 to 23.57. Leptin told a more nuanced story. After full adjustment, its relationship with MASLD risk was inverse U-shaped, meaning risk peaked at intermediate leptin concentrations rather than rising monotonically. Children in the middle tertile had an odds ratio of 6.70 compared with the lowest tertile, and the test for nonlinearity yielded a p-value of 0.004. Adiponectin and insulin-like growth factor 1, by contrast, lost any significant independent association once conventional risk factors were accounted for.
Association alone, however, does not make a biomarker clinically useful. The researchers therefore asked whether adding each protein to a base prediction model containing age, sex, BMI z-score, and waist-to-height ratio actually improved diagnostic performance. They evaluated this with three complementary metrics: the area under the receiver operating characteristic curve, which measures overall discrimination; the continuous net reclassification improvement, which quantifies how many patients are moved into more accurate risk categories; and the integrated discrimination improvement, which assesses gains in predicted probabilities. Individually, each biomarker produced only marginal and statistically non-significant increases in the optimism-corrected AUC—for example, adding cathepsin D yielded a change in AUC of 0.047 with a p-value of 0.096.
Yet the reclassification analyses told a more encouraging story. Incorporating cathepsin D produced the most prominent improvement in risk stratification, with a continuous net reclassification improvement of 1.147 (95 percent confidence interval 0.152 to 1.657, p = 0.032) and an integrated discrimination improvement of 0.142 (95 percent confidence interval 0.014 to 0.339, p = 0.008). Leptin and insulin-like growth factor 1 also generated significant reclassification gains, with all p-values below 0.05. In practical terms, this means that even when a biomarker does not dramatically shift the average discrimination statistic, it can still meaningfully re-sort individual children into more appropriate risk categories—correctly elevating the estimated risk of those who truly have hepatic steatosis and lowering it for those who do not. For a condition in which the decision to pursue further imaging or specialist referral hinges on risk thresholds, such reclassification can translate directly into better-targeted care.
The biological plausibility of the three signal-bearing markers strengthens the case. Cathepsin D’s strong association fits with its emerging role as a mediator of lysosomal lipid handling and inflammatory signaling in hepatocytes. The leptin finding is particularly intriguing: the inverse U-shaped curve suggests that both relatively low and very high leptin concentrations carry different risk implications than intermediate levels, a pattern that could reflect receptor desensitization, leptin’s dual roles in appetite regulation and hepatic fibrogenesis, or confounding by adiposity distribution that the adjustment model only partially captures. Growth differentiation factor 15’s positive association aligns with its established behavior as a marker of cellular metabolic stress, which would be expected to rise as hepatic fat accumulation imposes mitochondrial and inflammatory burdens on the liver.
The authors are careful to frame these results as preliminary. With only 84 participants, the confidence intervals are wide, and the odds ratios—especially the double-digit estimate for cathepsin D—carry substantial statistical uncertainty. The cross-sectional design also means the study captures a single snapshot; it demonstrates association, not causation, and cannot establish whether elevated cathepsin D or GDF15 precede the development of steatosis or accompany it. The single-center recruitment from one pediatric obesity clinic further limits generalizability, and ultrasound-based diagnosis, while standard in clinical practice, is an imperfect reference. The team explicitly calls for validation in larger, multicenter cohorts before these markers enter clinical decision-making. Still, the study was approved by the Tongji Hospital Ethics Committee and supported by China’s National Key Research and Development Program and the Natural Science Foundation of Hubei Province, and it offers a concrete, testable hypothesis: that a small panel of serum proteins, measured alongside routine anthropometry, could sharpen the non-invasive detection of MASLD in children. If larger studies confirm the reclassification gains observed here, pediatricians may one day identify which of their young patients with obesity carry silent liver disease with a routine blood test—catching, at an early and potentially reversible stage, a condition that otherwise hides in plain sight for decades.
Subject of Research: Serum cardiometabolic biomarkers for diagnosing metabolic dysfunction-associated steatotic liver disease in children with obesity
Article Title: Association and diagnostic value of serum cardiometabolic biomarkers for metabolic-associated steatotic liver disease in children with obesity
Article References: Wang, H., Yang, Z., Wu, S., Weng, Y., Hou, L., Wu, W., & Luo, X. (2026). Association and diagnostic value of serum cardiometabolic biomarkers for metabolic-associated steatotic liver disease in children with obesity. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07697-3
Image Credits: AI Generated
DOI: 10.1186/s12887-026-07697-3
Keywords: MASLD, pediatric obesity, cathepsin D, leptin, GDF15, biomarkers, fatty liver disease, non-invasive diagnosis, risk stratification, ELISA, children, hepatic steatosis
Cite Scienmag News
APA
MLA
Chicago
Daisy Hatcher. (September 30, 2026). Blood Proteins May Signal Fatty Liver Disease in Children with Obesity. Scienmag. https://scienmag.com/blood-proteins-may-signal-fatty-liver-disease-in-children-with-obesity/
Daisy Hatcher. “Blood Proteins May Signal Fatty Liver Disease in Children with Obesity.” Scienmag, 30 September 2026, https://scienmag.com/blood-proteins-may-signal-fatty-liver-disease-in-children-with-obesity/. Accessed 30 September 2026.
Daisy Hatcher. “Blood Proteins May Signal Fatty Liver Disease in Children with Obesity.” Scienmag. September 30, 2026. https://scienmag.com/blood-proteins-may-signal-fatty-liver-disease-in-children-with-obesity/
Copy citation
Download RIS
Tags: Biomarkersblood proteins as indicators of pediatric fatty liverblood-based screening for pediatric non-alcoholic fatty liver diseasecathepsin Dcathepsin D associated with pediatric metabolic liver diseasechildhood obesity and liver health monitoringChildrencirculating cardiometabolic biomarkers in pediatric liver diseaseearly detectionearly diagnosis of MASLD in obese childrenELISAfatty liver diseaseGDF15hepatic steatosisleptinleptin and growth differentiation factor 15 in childhood liver healthMASLDnon-invasive detection of childhood fatty livernon-invasive diagnosispediatric fatty liver disease blood biomarkerspediatric obesityrisk markers for fatty liver progression in childrenrisk stratification
